AJP - Gastrointestinal and Liver Physiology, Vol 273, Issue 1 112-G117, Copyright © 1997 by American Physiological Society

ARTICLES

Pancreatic spasmolytic polypeptide protects the gastric mucosa but does not inhibit acid secretion or motility

C. McKenzie, T. Marchbank, R. J. Playford, W. Otto, L. Thim and M. E. Parsons
Gastrointestinal Pharmacology Unit, University of Hertfordshire, Hatfield, United Kingdom.

The objectives of these studies were to examine whether the trefoil peptide porcine pancreatic spasmolytic polypeptide (PSP) had gastric mucosal protectant properties similar to its human equivalent human spasmolytic polypeptide (hSP) and to confirm the antisecretory and antimotility action of the peptide. PSP and recombinant hSP reduced gastric mucosal damage caused by a combination of subcutaneous indomethacin and restraint stress in the conscious rat. At a dose of 500 micrograms/kg bolus plus 500 micrograms.kg-1.h-1 sc, PSP significantly reduced the total area of damage by 58%. PSP at a dose of 150 micrograms/kg iv had no inhibitory effect on pentagastrin-stimulated gastric acid secretion in the perfused stomachs of anesthetized rats. This lack of antisecretory activity was confirmed in vitro using an isolated stomach preparation from the immature rat. PSP and hSP at concentrations up to 800 nM did not inhibit electrically or chemically evoked contractions of the guinea pig ileum and duodenum in vitro. Thus antisecretory and antimotility actions do not underlie the mucosal protectant properties of PSP. PSP did, however, stimulate cell migration, and this may, at least in part, account for its protectant properties.

This article has been cited by other articles:

				C. Fernandez-Estivariz, L. H. Gu, L. Gu, C. R. Jonas, T. M. Wallace, R. R. Pascal, K. L. Devaney, C. L. Farrell, D. P. Jones, D. K. Podolsky, et al. Trefoil peptide expression and goblet cell number in rat intestine: effects of KGF and fasting-refeeding Am J Physiol Regulatory Integrative Comp Physiol, February 1, 2003; 284(2): R564 - R573. [Abstract] [Full Text] [PDF]

				S S Poulsen, J Thulesen, L Christensen, E Nexo, and L Thim Metabolism of oral trefoil factor 2 (TFF2) and the effect of oral and parenteral TFF2 on gastric and duodenal ulcer healing in the rat Gut, October 1, 1999; 45(4): 516 - 522. [Abstract] [Full Text] [PDF]

				G. Langer, W. Jagla, W. Behrens-Baumann, S. Walter, and W. Hoffmann Secretory Peptides TFF1 and TFF3 Synthesized in Human Conjunctival Goblet Cells Invest. Ophthalmol. Vis. Sci., September 1, 1999; 40(10): 2220 - 2224. [Abstract] [Full Text] [PDF]

				C P Tran, G A Cook, N D Yeomans, L Thim, and A S Giraud Trefoil peptide TFF2 (spasmolytic polypeptide) potently accelerates healing and reduces inflammation in a rat model of colitis Gut, May 1, 1999; 44(5): 636 - 642. [Abstract] [Full Text] [PDF]

				T. Marchbank, H. M. Cox, R. A. Goodlad, A. S. Giraud, S. F. Moss, R. Poulsom, N. A. Wright, J. Jankowski, and R. J. Playford Effect of Ectopic Expression of Rat Trefoil Factor Family 3 (Intestinal Trefoil Factor) in the Jejunum of Transgenic Mice J. Biol. Chem., June 22, 2001; 276(26): 24088 - 24096. [Abstract] [Full Text] [PDF]